Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model
Open Access
- 15 October 2014
- journal article
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 307 (8) , F908-F916
Abstract
Semicarbazide-sensitive amine oxidase (SSAO) is an enzyme known for its dual function in mediating inflammation and reactive oxygen species production. However, the role of SSAO inhibitors in limiting kidney fibrosis is unclear. We aimed to determine the effectiveness of a SSAO inhibitor (SSAOi; PXS4728A) as an antifibrotic agent using a 7-day unilateral ureteric obstruction (UUO) model of acute kidney fibrosis in 6- to 8-wk-old mice. The experimental groups were 1) Sham operated; 2) UUO; 3) UUO+SSAOi (2 mg/kg); 4) UUO+telmisartan, an angiotensin receptor blocker (3 mg/kg); and 5) UUO+SSAOi+telmisartan. Kidney tissue was analyzed for histological evidence of tubulointerstitial fibrosis, nitrotyrosine staining, and mRNA expression of markers associated with fibrosis and inflammation. Kidney SSAO activity was determined by radiometric [14C]benzylamine methodology. Our results show that SSAOi effectively suppresses UUO-mediated SSAO activity. Extracellular matrix markers, namely, fibronectin, collagen IV protein, and nitrotyrosine staining, were lower in UUO+SSAOi mice compared with untreated UUO mice. This was consistent with the attenuated mRNA expression of collagen IV and fibronectin. SSAOi effectively inhibited transforming growth factor-β1 (TGF-β1) and monocyte chemoattractant protein-1 (MCP-1) expression to a similar extent to that observed with telmisartan. Individually, SSAOi and telmisartan induced a reduction in interstitial leukocyte and macrophage accumulation. However, the combination of SSAOi and telmisartan was more effective at reducing inflammatory cell infiltration. These results demonstrate that SSAO inhibition significantly suppresses profibrotic and proinflammatory cytokine secretion, reduces oxidative stress, and limits inflammatory cell accumulation and extracellular matrix expression in an acute model of renal fibrosis.Keywords
This publication has 27 references indexed in Scilit:
- Combined Angiotensin Inhibition for the Treatment of Diabetic NephropathyNew England Journal of Medicine, 2013
- PXS-4681A, a Potent and Selective Mechanism-Based Inhibitor of SSAO/VAP-1 with Anti-Inflammatory Effects In VivoThe Journal of Pharmacology and Experimental Therapeutics, 2013
- A comparison between radiometric and fluorimetric methods for measuring SSAO activityJournal of Neural Transmission, 2013
- Telmisartan Exerts Renoprotective Actions via Peroxisome Proliferator-Activated Receptor-γ/Hepatocyte Growth Factor Pathway Independent of Angiotensin II Type 1 Receptor BlockadeHypertension, 2012
- Mechanistic connection between inflammation and fibrosisKidney International, 2010
- VAP-1 and CD73, Endothelial Cell Surface Enzymes in Leukocyte ExtravasationArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Progression in Chronic Kidney DiseaseAdvances in Chronic Kidney Disease, 2005
- Chemokines and chemokine receptors are involved in the resolution or progression of renal diseaseKidney International, 2003
- Significance of Tubulointerstitial Changes in the Renal Cortex for the Excretory Function and Concentration Ability of the Kidney: A Morphometric ContributionAmerican Journal of Nephrology, 1987
- The Role of the Interstitium of the Renal Cortex in Renal Disease1979